Cargando…

LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain

Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descendi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Nannan, Li, Chunmei, Han, Rui, Wang, Yu, Yang, Mina, Wang, Hongbo, Tian, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382704/
https://www.ncbi.nlm.nih.gov/pubmed/30837867
http://dx.doi.org/10.3389/fphar.2019.00053
_version_ 1783396697023447040
author Li, Nannan
Li, Chunmei
Han, Rui
Wang, Yu
Yang, Mina
Wang, Hongbo
Tian, Jingwei
author_facet Li, Nannan
Li, Chunmei
Han, Rui
Wang, Yu
Yang, Mina
Wang, Hongbo
Tian, Jingwei
author_sort Li, Nannan
collection PubMed
description Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descending inhibitory pain pathway and sleep–wake cycle. The aim of this work was to test the hypothesis that LPM580098, a novel triple reuptake inhibitor (TRI) of 5-HT, NE, and DA, has analgesic effect, and does not induce significant adverse effects associated with central inhibition, such as sedation and somnolence. Methods: The analgesic activity of LPM580098 was assessed on formalin test and spinal nerve ligation (SNL)-induced neuropathic pain model. Locomotor activity, pentobarbital sodium-induced sleeping and rota-rod tests were also conducted. In vitro binding and uptake assays, and Western blotting were performed to examine the potential mechanisms. Results: LPM580098 suppressed the nocifensive behaviors during phase II of the formalin test in mice. In SNL rats, LPM580098 (16 mg kg(−1)) inhibited mechanical allodynia, thermal hyperalgesia and hyperexcitation of wide-dynamic range (WDR) neurons, in which the effect of LPM580098 was similar to pregabalin (30 mg kg(−1)). However, pregabalin altered the spontaneous locomotion, affected pentobarbital sodium-induced sleep, and showed a trend to perform motor dysfunction, which were not induced by LPM580098. Mechanistically, LPM580098 inhibited the uptake of 5-HT, NE, and DA, improved pain-induced changes of the synaptic functional plasticity and structural plasticity possibly via downregulating the NR2B/CaMKIIα/GluR1 and Rac1/RhoA signaling pathways. Conclusion: Our results suggest that LPM580098, a novel TRI, is effective in attenuating neuropathic pain without producing unwanted sedation and somnolence associated with central nervous system (CNS) depressants.
format Online
Article
Text
id pubmed-6382704
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63827042019-03-05 LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain Li, Nannan Li, Chunmei Han, Rui Wang, Yu Yang, Mina Wang, Hongbo Tian, Jingwei Front Pharmacol Pharmacology Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descending inhibitory pain pathway and sleep–wake cycle. The aim of this work was to test the hypothesis that LPM580098, a novel triple reuptake inhibitor (TRI) of 5-HT, NE, and DA, has analgesic effect, and does not induce significant adverse effects associated with central inhibition, such as sedation and somnolence. Methods: The analgesic activity of LPM580098 was assessed on formalin test and spinal nerve ligation (SNL)-induced neuropathic pain model. Locomotor activity, pentobarbital sodium-induced sleeping and rota-rod tests were also conducted. In vitro binding and uptake assays, and Western blotting were performed to examine the potential mechanisms. Results: LPM580098 suppressed the nocifensive behaviors during phase II of the formalin test in mice. In SNL rats, LPM580098 (16 mg kg(−1)) inhibited mechanical allodynia, thermal hyperalgesia and hyperexcitation of wide-dynamic range (WDR) neurons, in which the effect of LPM580098 was similar to pregabalin (30 mg kg(−1)). However, pregabalin altered the spontaneous locomotion, affected pentobarbital sodium-induced sleep, and showed a trend to perform motor dysfunction, which were not induced by LPM580098. Mechanistically, LPM580098 inhibited the uptake of 5-HT, NE, and DA, improved pain-induced changes of the synaptic functional plasticity and structural plasticity possibly via downregulating the NR2B/CaMKIIα/GluR1 and Rac1/RhoA signaling pathways. Conclusion: Our results suggest that LPM580098, a novel TRI, is effective in attenuating neuropathic pain without producing unwanted sedation and somnolence associated with central nervous system (CNS) depressants. Frontiers Media S.A. 2019-02-14 /pmc/articles/PMC6382704/ /pubmed/30837867 http://dx.doi.org/10.3389/fphar.2019.00053 Text en Copyright © 2019 Li, Li, Han, Wang, Yang, Wang and Tian. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Nannan
Li, Chunmei
Han, Rui
Wang, Yu
Yang, Mina
Wang, Hongbo
Tian, Jingwei
LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
title LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
title_full LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
title_fullStr LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
title_full_unstemmed LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
title_short LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
title_sort lpm580098, a novel triple reuptake inhibitor of serotonin, noradrenaline, and dopamine, attenuates neuropathic pain
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382704/
https://www.ncbi.nlm.nih.gov/pubmed/30837867
http://dx.doi.org/10.3389/fphar.2019.00053
work_keys_str_mv AT linannan lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain
AT lichunmei lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain
AT hanrui lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain
AT wangyu lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain
AT yangmina lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain
AT wanghongbo lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain
AT tianjingwei lpm580098anoveltriplereuptakeinhibitorofserotoninnoradrenalineanddopamineattenuatesneuropathicpain